YMTX News and Press, Yumanity Therapeutics Inc.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Photos by D / Shutterstock.com Vodafone (NASDAQ: VOD ) stock is on the move Monday as investors react to the company’s CEO stepping down after a poor year . Vodafone CEO Nick Read will leave the co...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: humphery / Shutterstock.com Chinese stocks are rallying on Monday as investors get more hopeful news of the country loosening its Covid-19 restrictions. Over the weekend, China reportedly let go of some of its r...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: jittawit21/Shutterstock.com Yumanity Therapeutics (NASDAQ: YMTX ) stock is rocketing higher on Monday after the clinical-stage biopharmaceutical company announced a special dividend . According to a press...

Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“...

Yumanity Therapeutics press release ( NASDAQ: YMTX ): Q3 GAAP EPS of -$0.31. Revenue of $1.4M (-14.6% Y/Y). For further details see: Yumanity Therapeutics GAAP EPS of -$0.31, revenue of $1.4M

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overvi...

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) today announced that the registration statement on Form S-4 (the “Registration Statement”), relating to the previously announced asset...

BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announce...

Yumanity Therapeutics press release ( NASDAQ: YMTX ): Q2 Non-GAAP EPS of -$0.45. Revenue of $1.66M (-21.3% Y/Y). As of June 30, 2022, cash, cash equivalents and investments were $11.8 million, compared to $36.5 million as of December 31, 2021. For further details...

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerativ...